News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
722,133 Results
Type
Article (42958)
Company Profile (441)
Press Release (678733)
Multimedia
Podcasts (90)
Webinars (16)
Section
Business (209045)
Career Advice (2068)
Deals (36073)
Drug Delivery (104)
Drug Development (83772)
Employer Resources (173)
FDA (16546)
Job Trends (15156)
News (353531)
Policy (33190)
Tag
Academia (2666)
Accelerated approval (11)
Adcomms (26)
Allergies (98)
Alliances (51179)
ALS (114)
Alzheimer's disease (1498)
Antibody-drug conjugate (ADC) (168)
Approvals (16526)
Artificial intelligence (331)
Autoimmune disease (33)
Automation (19)
Bankruptcy (373)
Best Places to Work (11863)
BIOSECURE Act (19)
Biosimilars (123)
Biotechnology (333)
Bladder cancer (98)
Brain cancer (36)
Breast cancer (374)
Cancer (2954)
Cardiovascular disease (226)
Career advice (1730)
Career pathing (30)
CAR-T (194)
CDC (32)
Cell therapy (527)
Cervical cancer (22)
Clinical research (68731)
Collaboration (1067)
Company closure (3)
Compensation (699)
Complete response letters (27)
COVID-19 (2699)
CRISPR (64)
C-suite (339)
Cystic fibrosis (118)
Data (3046)
Decentralized trials (2)
Denatured (31)
Depression (70)
Diabetes (351)
Diagnostics (6493)
Digital health (24)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (148)
Drug pricing (130)
Drug shortages (29)
Duchenne muscular dystrophy (131)
Earnings (88715)
Editorial (44)
Employer branding (21)
Employer resources (149)
Events (117504)
Executive appointments (873)
FDA (18219)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (10)
Funding (976)
Gene editing (141)
Generative AI (24)
Gene therapy (405)
GLP-1 (825)
Government (4604)
Grass and pollen (4)
Guidances (181)
Healthcare (19219)
HIV (42)
Huntington's disease (31)
IgA nephropathy (43)
Immunology and inflammation (163)
Immuno-oncology (8)
Indications (40)
Infectious disease (2876)
Inflammatory bowel disease (156)
Inflation Reduction Act (13)
Influenza (65)
Intellectual property (122)
Interviews (322)
IPO (16883)
IRA (47)
Job creations (3713)
Job search strategy (1467)
Kidney cancer (13)
Labor market (52)
Layoffs (525)
Leadership (21)
Legal (8014)
Liver cancer (80)
Longevity (11)
Lung cancer (414)
Lymphoma (211)
Machine learning (11)
Management (58)
Manufacturing (398)
MASH (94)
Medical device (13662)
Medtech (13667)
Mergers & acquisitions (19909)
Metabolic disorders (886)
Multiple sclerosis (100)
NASH (19)
Neurodegenerative disease (129)
Neuropsychiatric disorders (39)
Neuroscience (2216)
NextGen: Class of 2025 (6772)
Non-profit (4569)
Now hiring (47)
Obesity (451)
Opinion (238)
Ovarian cancer (103)
Pain (111)
Pancreatic cancer (121)
Parkinson's disease (193)
Partnered (22)
Patents (303)
Patient recruitment (168)
Peanut (51)
People (59148)
Pharmaceutical (86)
Pharmacy benefit managers (22)
Phase I (21603)
Phase II (30330)
Phase III (22399)
Pipeline (1662)
Policy (211)
Postmarket research (2603)
Preclinical (9287)
Press Release (68)
Prostate cancer (146)
Psychedelics (43)
Radiopharmaceuticals (272)
Rare diseases (488)
Real estate (6031)
Recruiting (67)
Regulatory (23123)
Reports (50)
Research institute (2435)
Resumes & cover letters (355)
Rett syndrome (9)
RNA editing (10)
RSV (49)
Schizophrenia (95)
Series A (170)
Series B (116)
Service/supplier (11)
Sickle cell disease (66)
Special edition (21)
Spinal muscular atrophy (153)
Sponsored (33)
Startups (3781)
State (2)
Stomach cancer (15)
Supply chain (77)
Tariffs (57)
The Weekly (57)
Vaccines (807)
Venture capital (56)
Weight loss (278)
Women's health (49)
Worklife (17)
Date
Today (58)
Last 7 days (385)
Last 30 days (1913)
Last 365 days (32089)
2025 (17242)
2024 (36340)
2023 (41056)
2022 (52313)
2021 (56818)
2020 (55021)
2019 (47514)
2018 (35781)
2017 (33102)
2016 (32416)
2015 (38480)
2014 (32251)
2013 (27178)
2012 (29297)
2011 (29913)
2010 (28056)
Location
Africa (739)
Alabama (67)
Alaska (7)
Arizona (251)
Arkansas (14)
Asia (39735)
Australia (6604)
California (7601)
Canada (2376)
China (694)
Colorado (328)
Connecticut (333)
Delaware (195)
Europe (87065)
Florida (1125)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (660)
India (27)
Indiana (365)
Iowa (18)
Japan (232)
Kansas (111)
Kentucky (30)
Louisiana (15)
Maine (64)
Maryland (1044)
Massachusetts (5746)
Michigan (248)
Minnesota (458)
Mississippi (3)
Missouri (91)
Montana (30)
Nebraska (25)
Nevada (80)
New Hampshire (70)
New Jersey (2118)
New Mexico (30)
New York (2120)
North Carolina (1149)
North Dakota (9)
Northern California (3320)
Ohio (239)
Oklahoma (16)
Oregon (38)
Pennsylvania (1629)
Puerto Rico (17)
Rhode Island (37)
South America (1115)
South Carolina (34)
South Dakota (1)
Southern California (2829)
Tennessee (126)
Texas (1147)
United States (28268)
Utah (223)
Virginia (190)
Washington D.C. (75)
Washington State (658)
West Virginia (4)
Wisconsin (70)
722,133 Results for "adaptive phage therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
BiomX Inc. today announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections (the “Acquisition”).
March 6, 2024
·
15 min read
Deals
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
BiomX Inc. announced the closing of its previously announced acquisition of Adaptive Phage Therapeutics, Inc. and its previously announced $50 million private placement to certain institutional accredited investors, which was led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital.
March 18, 2024
·
11 min read
Press Releases
ZeptoMetrix Launches H5N1 Control With Phage-Like Particle (PLP) Technology
June 24, 2025
·
2 min read
Press Releases
BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis
July 9, 2025
·
8 min read
Business
Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center
Adaptive Phage Therapeutics is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center.
May 24, 2023
·
7 min read
BioCapital
Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection
Adaptive Phage Therapeutics, Inc., today announced the first patient has been dosed in the PHAGE clinical trial, evaluating bacteriophage therapy in adults with cystic fibrosis (CF) who carry Pseudomonas aeruginosa ( P. aeruginosa ) in their lungs.
January 12, 2023
·
5 min read
Business
Adaptive Phage Therapeutics Appoints Edward Fang as Chief Medical Officer
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing a phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced the appointment of Edward Fang, M.D. as Chief Medical Officer.
October 25, 2022
·
3 min read
BioCapital
Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections
Adaptive Phage Therapeutics announced that it has received a $12 million upfront investment from funds managed by Deerfield Management and the AMR Action Fund as part of a new $24 million total investment in a Series B1 round that is targeting $30 million in aggregate.
June 13, 2023
·
4 min read
BioCapital
Adaptive Phage Therapeutics Announces “The AMR RAPID™ Challenge” for the Infectious Disease Research Community: Find a Bacteria Resistant to APT’s Investigational Phage Bank
Adaptive Phage Therapeutics, Inc. announced “The AMR RAPID™ Challenge” at the World AMR Congress.
September 7, 2022
·
2 min read
Press Releases
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
July 2, 2025
·
7 min read
1 of 72,214
Next